Thèse : Médecine : Paris : 1911. / N° d'ordre :173.

No description available.

Thesis (Ph. D.)--University of Wisconsin--Madison, 1976. / Typescript. Vita. Includes bibliographical references (leaves 94-102).

Thesis--University of Wisconsin--Madison. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 197-213).

Thesis--Wisconsin. / Vita. Includes bibliographical references (leaves 158-180).

Thesis (M.S.)--University of Wisconsin--Madison, 1964. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (M.Sc.)--University of the Witwatersrand, Faculty of Science, 1968.

Thesis (Ph.D.)--Murdoch University, 2007. / Thesis submitted to the Division of Health Sciences. Includes bibliographical references (leaves 241-273)

Thesis (Ph. D.)--University of Wisconsin--Madison, 1963. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 104-108).

Thesis (MTech (Biomedical Technology))--Cape Peninsula University of Technology, 2009. / The main objective of radiotherapy is to completely eradicate tumours while preserving the integrity of the normal surrounding tissue. The severity of normal tissue reactions varies considerably amongst individuals. Following the same treatment regime for individuals with identical tumours in terms of location, pathology and size might result in adverse tissue reactions for some while others may experience no adverse reactions. Based on this principle some individuals who are more radiosensitive than others are receiving beyond normal tissue tolerance doses while others, who are more radioresistant, receive sub-tolerance doses. These differences in response to radiation are a concern for both the patient and the oncologist. For these reasons it is essential to predict individual responses to radiotherapy in order to optimise the treatment regime for each patient. The development of predictive assays for normal tissue reactions are in the early stages and not routinely used in laboratories. Qualities of a predictive assay should include the capacity to distinguish between small changes in individual radiosensitivity. These assays should also be easy and quick to perform so that it can be employed during the initial treatment planning phase for therapy. Also, the assay should be inexpensive enough to be used on a daily basis in the clinic.